Clinical Trials Logo

Leukemia, Mast-Cell clinical trials

View clinical trials related to Leukemia, Mast-Cell.

Filter by:

NCT ID: NCT05219266 Available - Clinical trials for Acute Myeloid Leukemia

Managed Access Programs for PKC412, Midostaurin

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this registration is to list Managed Access Programs (MAPs) related to PKC4, Midostaurin.

NCT ID: NCT04996875 Recruiting - Clinical trials for Aggressive Systemic Mastocytosis (ASM)

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Start date: November 9, 2021
Phase: Phase 2
Study type: Interventional

This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).

NCT ID: NCT04695431 Completed - Mast Cell Leukemia Clinical Trials

Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM

Start date: December 2, 2020
Phase:
Study type: Observational

BLU-285-2405 is a multi-center, synthetic control, observational and retrospective study designed to compare clinical outcomes for avapritinib compared with best available therapy for patients with AdvSM.

NCT ID: NCT03580655 Active, not recruiting - Mast Cell Leukemia Clinical Trials

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Start date: November 21, 2018
Phase: Phase 2
Study type: Interventional

This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive SM (ASM), SM with associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL)

NCT ID: NCT03214666 Terminated - Clinical trials for Acute Myelogenous Leukemia

GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies

Start date: January 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multi-center Phase I/II clinical trial of GTB-3550 (CD16/IL-15/CD33) tri-specific killer cell engager (TriKE®) for the treatment of CD33-expressing high risk myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis. The hypothesis is that GTB-3550 TriKE® will induce natural killer cell function by targeting malignant cells as well as CD33+ myeloid derived suppressor cells (MDSC) which contribute to tumor induced immunosuppression. Because CD16 is the most potent activating receptor on natural killer (NK) cells, this single agent may induce a targeted anti-CD33+ tumor response.

NCT ID: NCT02561988 Completed - Mast Cell Leukemia Clinical Trials

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Start date: March 10, 2016
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (also known as BLU-285), administered orally (PO), in adult patients with advanced systemic mastocytosis and other relapsed or refractory myeloid malignancies. The study consists of 2 parts:, dose-escalation (Part 1) and expansion (Part 2).

NCT ID: NCT02415608 Terminated - Mast Cell Leukemia Clinical Trials

Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

Start date: March 2015
Phase: Phase 2
Study type: Interventional

This phase 2 trial studies ibrutinib to see how well it works in treating patients with systemic (affecting the entire body) mastocytosis that has spread to other parts of the body and usually cannot be cured or controlled with treatment (advanced). Systemic mastocytosis is a disease in which too many mast cells (a type of immune system cell) are found throughout the body. Mast cells give off chemicals such as histamine that can cause flushing (a hot, red face), itching, abdominal cramps, muscle pain, nausea, vomiting, diarrhea, low blood pressure, and shock. Ibrutinib may stop the growth of mast cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02380222 Completed - Clinical trials for Aggressive Systemic Mastocytosis (ASM)

Patient-Reported Outcome Questionnaire for Systemic Mastocytosis

Start date: July 2014
Phase: N/A
Study type: Observational

The purpose of this study is to explore the key symptoms of individuals with systemic mastocytosis. Interviews of enrolled individuals will be conducted to learn about the disease symptoms and condition. The interview will last approximately 60 minutes and will be conducted by a trained interviewer, be audio-recorded (with patient consent), and all information provided by the patient will be treated confidentially and made anonymous so that it is non-identifiable. The interview may be conducted face-to-face, over the phone, or virtually via Skype, a free video conferencing program, depending upon the patient's geographic location. Patients will be compensated for their participating time. This is not a medication-related study, and no medication will be distributed or tested during this study. Participation in this study will not affect any treatment or assistance that a patient currently receives or may receive in the future.

NCT ID: NCT01869777 Completed - Clinical trials for Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia

Start date: July 2013
Phase: N/A
Study type: Interventional

This clinical trial studies bioelectrical impedance measurement for predicting treatment outcome in patients with newly diagnosed acute leukemia. Diagnostic procedures, such as bioelectrical impedance measurement, may help predict a patient's response to treatment for acute leukemia.

NCT ID: NCT01807598 Completed - Mast Cell Leukemia Clinical Trials

Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia

Start date: September 2013
Phase: Phase 2
Study type: Interventional

This pilot clinical trial studies brentuximab vedotin in treating patients with advanced systemic mastocytosis or mast cell leukemia. Monoclonal antibodies, such as brentuximab vedotin, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them